Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 683Carcinoma, Renal Cell 225Urinary Bladder Neoplasms 195Carcinoma, Transitional Cell 111Breast Neoplasms 96Kidney Neoplasms 89Carcinoma, Non-Small-Cell Lung 82Neoplasms 81Melanoma 78Ovarian Neoplasms 77Colorectal Neoplasms 68Neoplasm Metastasis 66Non-Muscle Invasive Bladder Neoplasms 56Lung Neoplasms 53Pancreatic Neoplasms 46Sarcoma 45Stomach Neoplasms 42Endometrial Neoplasms 41Uterine Cervical Neoplasms 39Wilms Tumor 33Adenocarcinoma 33Esophageal Neoplasms 31Carcinoma, Hepatocellular 31Squamous Cell Carcinoma of Head and Neck 30Triple Negative Breast Neoplasms 29Head and Neck Neoplasms 27Testicular Neoplasms 24Metastatic Castration-resistant Prostate Cancer 24Neuroblastoma 23Colonic Neoplasms 23

Interventions

sipuleucel-T 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Genitourinary × 90 days × Clear all
NCT05806814 2026-05-27

OU-SCC-EXCITE

University of Oklahoma

Phase 1 Active not recruiting
15 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05658003 2026-03-23

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Novartis

Phase 2 Active not recruiting
63 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡